Version 1
: Received: 30 June 2023 / Approved: 3 July 2023 / Online: 3 July 2023 (13:25:11 CEST)
How to cite:
Danzmann, L.C.; Forestiero, F.; Catucci, R.F.; Tosetto, N. Sacubitril-Valsartan and Its Results for the Treatment of Heart Failure with Preserved and Mildly Reduced Ejection Fraction. Preprints2023, 2023070090. https://doi.org/10.20944/preprints202307.0090.v1
Danzmann, L.C.; Forestiero, F.; Catucci, R.F.; Tosetto, N. Sacubitril-Valsartan and Its Results for the Treatment of Heart Failure with Preserved and Mildly Reduced Ejection Fraction. Preprints 2023, 2023070090. https://doi.org/10.20944/preprints202307.0090.v1
Danzmann, L.C.; Forestiero, F.; Catucci, R.F.; Tosetto, N. Sacubitril-Valsartan and Its Results for the Treatment of Heart Failure with Preserved and Mildly Reduced Ejection Fraction. Preprints2023, 2023070090. https://doi.org/10.20944/preprints202307.0090.v1
APA Style
Danzmann, L.C., Forestiero, F., Catucci, R.F., & Tosetto, N. (2023). Sacubitril-Valsartan and Its Results for the Treatment of Heart Failure with Preserved and Mildly Reduced Ejection Fraction. Preprints. https://doi.org/10.20944/preprints202307.0090.v1
Chicago/Turabian Style
Danzmann, L.C., Raphael Fernandes Catucci and Nivia Tosetto. 2023 "Sacubitril-Valsartan and Its Results for the Treatment of Heart Failure with Preserved and Mildly Reduced Ejection Fraction" Preprints. https://doi.org/10.20944/preprints202307.0090.v1
Abstract
Background: The 2021 “Universal Definition of Heart Failure (HF)” Proposed the following left ventricle ejection (LVEF) phenotype classification: ≤40%; HF with intermediate LVEF: between 41-49% and HF with preserved LVEF: ≥50%. LVEF represents the percentage of left ventricular ejected volume in each cardiac cycle and Cut-points considered statistically normal are: ≥52% in men and ≥54% in women. The prevalence HFpEF is of 35-60% among the HF phenotypes, with a facing to increase rates in relation to HFrEF and is associated with mortality rates similar to those of HFrEF. The pathophysiology of HFpEF is based on vascular and metabolic dysfunction, therefore, there is less neurohumoral stimulation compared to HFrEF. Methodology: A systematic review was performed to report of information related to Sacubitril-valsartan and the treatment of HFrEF. Terms related to “treatment” and “brazil” were used in the databases PubMed (MEDLINE) and Scientific Electronic Library Online (SCIELO). Results: Clinical trials testing drugs that modulate the neurohumoral system in patients with HFpEF failed to demonstrate benefit in the combined endpoint of reduced mortality/hospitalization due to HF compared to placebo to date. Sacubitril-valsartan is a drug with a mechanism of action surrogate the pathophysiological concept of HFpEF, it is safe and decreased endpoints of natriuretic peptides and left atrial structure in a phase II clinical study. Conclusions: The PARAGON-HF trial demonstrated that sacubitril-valsartan reduced the primary endpoint of the study when assessed the pre-specified subgroup of LVEF≤57% and improved the secondary endpoints of performance status and renal function in the population.
Keywords
Sacubitril-valsartan; heart failure; ejection fraction and cardiovascular disease
Subject
Public Health and Healthcare, Public Health and Health Services
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
